Islet autoantibody testing: An end to the trials and tribulations?

Diabetes

Volumn 62, Issue 12, 2013, Pages 4009-4011

  Bingley, Polly J ^a   Williams, Alistair J K ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; INSULIN ANTIBODY; ISLET ANTIGEN 2; PANCREAS ISLET CELL ANTIBODY; UNCLASSIFIED DRUG; ZINC TRANSPORTER;

ANTIBODY DETECTION; AUTOIMMUNITY; CHEMOLUMINESCENCE; ELECTROCHEMILUMINESCENCE; GENETIC RISK; HUMAN; IMMUNOASSAY; INSULIN DEPENDENT DIABETES MELLITUS; NOTE; PANCREAS ISLET CELL AUTOANTIBODY TEST; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; PREDIABETIC STATE;

EID: 84891767179     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1445     Document Type: Note

References (20)

1. Gorsuch AN, Spencer KM, Lister J, et al. Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus. Lancet 1981;2:1363-1365
2. Barker JM, Barriga KJ, Yu L, et al.; Diabetes Autoimmunity Study in the Young. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004;89:3896-3902
3. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013; 309:2473-2479
4. Parikka V, Näntö-Salonen K, Saarinen M, et al. Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk. Diabetologia 2012; 55:1926-1936
5. Vehik K, Fiske SW, Logan CA, et al.; the TEDDY Study Group. Methods, quality control and specimen management in an international multicentre investigation of type 1 diabetes: TEDDY. Diabetes Metab Res Rev 2013;29: 557-567
6. Bingley PJ. Clinical applications of diabetes antibody testing. J Clin Endocrinol Metab 2010;95:25-33
7. Törn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008;51:846-852
8. Schlosser M, Mueller PW, Törn C, Bonifacio E, Bingley PJ; Participating Laboratories. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010;53:2611-2620
9. Liu E, Eisenbarth GS. Accepting clocks that tell time poorly: fluid-phase versus standard ELISA autoantibody assays. Clin Immunol 2007;125:120-126
10. Miao D, Guyer KM, Dong F, et al. GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes. Diabetes 2013;62:4174-4178
11. Yu L, Miao D, Scrimgeour L, Johnson K, Rewers M, Eisenbarth GS. Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes 2012; 61:179-186
12. Yu L, Dong F, Miao D, Fouts AR, Wenzlau JM, Steck AK. Proinsulin/insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity. Diabetes Care 2013;36: 2266-2270
13. Achenbach P, Warncke K, Reiter J, et al. Stratification of type 1 diabetes risk on the basis of islet autoantibody characteristics. Diabetes 2004;53: 384-392
14. Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004;114:589-597
15. Achenbach P, Schlosser M, Williams AJ, et al. Combined testing of antibody titer and affinity improves insulin autoantibody measurement: Diabetes Antibody Standardization Program. Clin Immunol 2007;122:85-90
16. Castaño L, Ziegler AG, Ziegler R, Shoelson S, Eisenbarth GS. Characterization of insulin autoantibodies in relatives of patients with type I diabetes. Diabetes 1993;42:1202-1209
17. Kim J, Namchuk M, Bugawan T, et al. Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus. J Exp Med 1994;180:595-606
18. Bearzatto M, Naserke H, Piquer S, et al. Two distinctly HLA-associated contiguous linear epitopes uniquely expressed within the islet antigen 2 molecule are major autoantibody epitopes of the diabetes-specific tyrosine phosphatase-like protein autoantigens. J Immunol 2002;168: 4202-4208
19. Brooking H, Ananieva-Jordanova R, Arnold C, et al. A sensitive non-isotopic assay for GAD65 autoantibodies. Clin Chim Acta 2003;331:55-59
20. Burbelo PD, Hirai H, Issa AT, et al. Comparison of radioimmunoprecipitation with luciferase immunoprecipitation for autoantibodies to GAD65 and IA-2b. Diabetes Care 2010;33:754-756